BACKGROUND: Platelet aggregation plays a critical role in myocardial infarction and stroke; however, the role of platelet secretion in atherosclerotic vascular disease is poorly understood. Therefore, we examined the hypothesis that platelet dense-granule secretion modulates thrombosis, inflammation, and atherosclerotic vascular remodeling after injury. METHODS AND RESULTS: Functional deletion of the Hermansky-Pudlak syndrome 3 gene (HPS3(-/-)) markedly reduces platelet dense-granule secretion. HPS3(-/-) mice have normal platelet counts, platelet morphology, and alpha-granule number, as well as maximal secretion of the alpha-granule marker P-selectin; however, their capacity to form platelet-leukocyte aggregates is significantly reduced (P<0.05). To examine the role of platelet dense-granule secretion in these processes, atherosclerosis-prone mice with combined genetic deficiency of apolipoprotein E and HPS3 (ApoE(-/-), HPS3(-/-)) were compared with congenic, atherosclerosis-prone mice with normal platelet secretion (ApoE(-/-), HPS3(+/+)). After 16 to 18 weeks on a high-fat diet, both groups of mice had similar fasting cholesterol levels and body weight. Carotid arteries of ApoE(-/-), HPS3(+/+) mice thrombosed rapidly after FeCl(3) injury, but ApoE(-/-), HPS3(-/-) mice were completely resistant to thrombotic arterial occlusion (P<0.01). Three weeks after injury, neointimal hyperplasia (from alpha-smooth muscle actin-positive cells) was significantly less (P<0.001) in arteries from ApoE(-/-), HPS3(-/-) mice. In ApoE(-/-), HPS3(-/-) mice, there were also pronounced reductions in arterial inflammation, as indicated by a 74% decrease in CD45-positive leukocytes (P<0.01) and a 73% decrease in Mac-3-positive macrophages (P<0.05). CONCLUSIONS: In atherosclerotic mice, reduced platelet dense-granule secretion is associated with marked protection against the development of arterial thrombosis, inflammation, and neointimal hyperplasia after vascular injury.
BACKGROUND:Platelet aggregation plays a critical role in myocardial infarction and stroke; however, the role of platelet secretion in atherosclerotic vascular disease is poorly understood. Therefore, we examined the hypothesis that platelet dense-granule secretion modulates thrombosis, inflammation, and atherosclerotic vascular remodeling after injury. METHODS AND RESULTS: Functional deletion of the Hermansky-Pudlak syndrome 3 gene (HPS3(-/-)) markedly reduces platelet dense-granule secretion. HPS3(-/-) mice have normal platelet counts, platelet morphology, and alpha-granule number, as well as maximal secretion of the alpha-granule marker P-selectin; however, their capacity to form platelet-leukocyte aggregates is significantly reduced (P<0.05). To examine the role of platelet dense-granule secretion in these processes, atherosclerosis-prone mice with combined genetic deficiency of apolipoprotein E and HPS3 (ApoE(-/-), HPS3(-/-)) were compared with congenic, atherosclerosis-prone mice with normal platelet secretion (ApoE(-/-), HPS3(+/+)). After 16 to 18 weeks on a high-fat diet, both groups of mice had similar fasting cholesterol levels and body weight. Carotid arteries of ApoE(-/-), HPS3(+/+) mice thrombosed rapidly after FeCl(3) injury, but ApoE(-/-), HPS3(-/-) mice were completely resistant to thrombotic arterial occlusion (P<0.01). Three weeks after injury, neointimal hyperplasia (from alpha-smooth muscle actin-positive cells) was significantly less (P<0.001) in arteries from ApoE(-/-), HPS3(-/-) mice. In ApoE(-/-), HPS3(-/-) mice, there were also pronounced reductions in arterial inflammation, as indicated by a 74% decrease in CD45-positive leukocytes (P<0.01) and a 73% decrease in Mac-3-positive macrophages (P<0.05). CONCLUSIONS: In atheroscleroticmice, reduced platelet dense-granule secretion is associated with marked protection against the development of arterial thrombosis, inflammation, and neointimal hyperplasia after vascular injury.
Authors: Yuqing Huo; Andreas Schober; S Bradley Forlow; David F Smith; Matthew Craig Hyman; Steffen Jung; Dan R Littman; Christian Weber; Klaus Ley Journal: Nat Med Date: 2002-12-16 Impact factor: 53.440
Authors: T Suzuki; W Li; Q Zhang; E K Novak; E V Sviderskaya; A Wilson; D C Bennett; B A Roe; R T Swank; R A Spritz Journal: Genomics Date: 2001-11 Impact factor: 5.736
Authors: M P Savage; S Goldberg; A A Bove; E Deutsch; G Vetrovec; R G Macdonald; T Bass; J R Margolis; H B Whitworth; A Taussig Journal: Circulation Date: 1995-12-01 Impact factor: 29.690
Authors: Jose María Bastida; Sara Morais; Veronica Palma-Barqueros; Rocio Benito; Nuria Bermejo; Mutlu Karkucak; Maria Trapero-Marugan; Natalia Bohdan; Mónica Pereira; Ana Marin-Quilez; Jorge Oliveira; Yusuf Yucel; Rosario Santos; Jose Padilla; Kamila Janusz; Catarina Lau; Marta Martin-Izquierdo; Eduarda Couto; Juan Francisco Ruiz-Pividal; Vicente Vicente; Jesus Maria Hernández-Rivas; Jose Ramon González-Porras; Maria Luisa Lozano; Margarida Lima; Jose Rivera Journal: Ann Med Date: 2019-04-16 Impact factor: 4.709
Authors: Theodora A M Claushuis; Alex F de Vos; Joris J T H Roelofs; Onno J de Boer; Cornelis van 't Veer; Tom van der Poll Journal: J Innate Immun Date: 2018-12-17 Impact factor: 7.349
Authors: Lilia Y Kucheryavykh; Josué Dávila-Rodríguez; David E Rivera-Aponte; Lidia V Zueva; A Valance Washington; Priscilla Sanabria; Mikhail Y Inyushin Journal: Brain Res Bull Date: 2016-11-28 Impact factor: 4.077
Authors: Bo Rong Zhou; Hong Ting Shi; Rong Wang; Min Zhang; Hai Tao Guan; Zi Fan Liu; Yan Hua Deng Journal: J Neurol Date: 2013-10-18 Impact factor: 4.849
Authors: Cassidy Delaney; Pavel Davizon-Castillo; Ayed Allawzi; Janelle Posey; Aneta Gandjeva; Keith Neeves; Rubin M Tuder; Jorge Di Paola; Kurt R Stenmark; Eva S Nozik Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-12-02 Impact factor: 5.464